NASDAQ:AVDL Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. $9.16 +0.64 (+7.51%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.57▼$9.2850-Day Range$6.99▼$9.9552-Week Range$1.05▼$10.20Volume2.20 million shsAverage Volume394,118 shsMarket Capitalization$565.90 millionP/E RatioN/ADividend YieldN/APrice Target$12.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avadel Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside32.6% Upside$12.14 Price TargetShort InterestBearish6.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 20 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.90) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector752nd out of 1,004 stocksPharmaceutical Preparations Industry371st out of 489 stocks 3.4 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.14, Avadel Pharmaceuticals has a forecasted upside of 32.6% from its current price of $9.16.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.89% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 0.25%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 2.4 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Avadel Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows6 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions50.81% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.90) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avadel Pharmaceuticals (NASDAQ:AVDL) StockAvadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.Read More Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Stock News HeadlinesApril 1, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)March 31, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)April 1, 2023 | Investorplace Media (Ad)5 Hypergrowth Stocks to Buy NowLuke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. March 31, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Trading Down 2.6%March 30, 2023 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred SharesMarch 30, 2023 | msn.comEarnings Scheduled For March 30, 2023March 30, 2023 | finance.yahoo.comAvadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 30, 2023 | finance.yahoo.comAvadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsApril 1, 2023 | Investorplace Media (Ad)5 Hypergrowth Stocks to Buy NowLuke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. March 30, 2023 | finance.yahoo.comAvadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred SharesMarch 30, 2023 | finance.yahoo.comAvadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30March 29, 2023 | finance.yahoo.comAvadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 MillionMarch 29, 2023 | finance.yahoo.comAvadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred SharesMarch 29, 2023 | americanbankingnews.comBrokerages Set Avadel Pharmaceuticals plc (NASDAQ:AVDL) Price Target at $12.14March 28, 2023 | americanbankingnews.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) to Post FY2023 Earnings of ($1.42) Per Share, HC Wainwright ForecastsMarch 26, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Avadel Pharmaceuticals (AVDL), CVRx (CVRX)March 24, 2023 | americanbankingnews.comHC Wainwright Weighs in on Avadel Pharmaceuticals plc's FY2024 Earnings (NASDAQ:AVDL)March 24, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Given New $14.00 Price Target at HC WainwrightMarch 22, 2023 | marketwatch.comAvadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ(TM) Ahead of Anticipated Final Approval DecisionMarch 22, 2023 | markets.businessinsider.comAvadel Pharma Says FDA Approves Pre-Launch Activities Importation Requests For LUMRYZMarch 22, 2023 | msn.comAvadel stock rises on FDA nod to import sleep disorder drug Lumryz ahead of potential approvalMarch 22, 2023 | finance.yahoo.comAvadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval DecisionMarch 18, 2023 | money.usnews.comAvadel Pharmaceuticals plc - ADRMarch 14, 2023 | seekingalpha.comAvadel Pharmaceuticals: Real-World Data Supports Market Opportunity For LumryzMarch 2, 2023 | markets.businessinsider.comAvadel Seeks Final FDA Approval For Lumryz For Treatment Of Cataplexy In Adults With NarcolepsyMarch 2, 2023 | finance.yahoo.comAvadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspensionFebruary 28, 2023 | finance.yahoo.comAvadel Pharmaceuticals Shows Big Promise -- And RiskSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Company Calendar Last Earnings11/08/2021Today4/01/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees66Year Founded2015Price Target and Rating Average Stock Price Forecast$12.14 High Stock Price Forecast$20.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+32.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-334.88% Return on Assets-51.04% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual Sales$22.33 million Price / Sales25.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book6.89Miscellaneous Outstanding Shares61,780,000Free Float59,802,000Market Cap$565.90 million OptionableOptionable Beta1.49 Social Links Key ExecutivesGregory J. DivisChief Executive Officer & DirectorScott MackeVice President-Supply Chain & OperationsThomas S. McHughChief Financial Officer & Senior Vice PresidentJason VaughnSenior Vice President-Technical OperationsJennifer GudemanVice President-Medical & Clinical AffairsKey CompetitorsAclaris TherapeuticsNASDAQ:ACRSMorphoSysNASDAQ:MORZymeworksNYSE:ZYMEAldeyra TherapeuticsNASDAQ:ALDXProcaps GroupNASDAQ:PROCView All CompetitorsInsiders & InstitutionsRockefeller Capital Management L.P.Bought 3,294 shares on 3/6/2023Ownership: 0.006%State of WyomingBought 4,001 shares on 2/16/2023Ownership: 0.047%DRW Securities LLCBought 27,000 shares on 2/15/2023Ownership: 0.000%Virtu Financial LLCBought 4,769 shares on 2/15/2023Ownership: 0.025%Belvedere Trading LLCBought 1,500 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AVDL Stock - Frequently Asked Questions Should I buy or sell Avadel Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks. What is Avadel Pharmaceuticals' stock price forecast for 2023? 7 equities research analysts have issued 12 month price objectives for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $12.14 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts. How have AVDL shares performed in 2023? Avadel Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, AVDL stock has increased by 27.9% and is now trading at $9.16. View the best growth stocks for 2023 here. When is Avadel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our AVDL earnings forecast. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.38) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.38). During the same quarter in the previous year, the business posted ($0.20) earnings per share. What ETFs hold Avadel Pharmaceuticals' stock? ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY). What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $9.16. How much money does Avadel Pharmaceuticals make? Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $565.90 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 901-5201, via email at investors@avadel.com, or via fax at 353-1526-1077. This page (NASDAQ:AVDL) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.